NEMAURA MEDICAL INC - NMRD STOCK NEWS

Nemaura Medical, Inc. (NASDAQ: NMRD) has completed its initial shipment of sugarBEAT® continuous glucose monitor (CGM) devices to UK licensee MySugarWatch. This milestone allows the company to recognize revenue for the first time in its history. MySugarWatch will sell the CGM along with a subscription diabetes coaching service targeting type 2 diabetes. With over 4.9 million people diagnosed with diabetes in the UK, the partnership aims to improve patient outcomes. MySugarWatch has ordered 5,000 CGM devices and 200,000 sensors, with future orders projected up to 2 million sensors and 15,000 CGM devices.

Nemaura Medical, a medical technology firm focused on non-invasive diagnostic devices, will have CEO Faz Chowdhury present at the Benzinga Global Small Cap Conference virtually from December 8-9, 2021. Chowdhury's presentation is scheduled for December 8 at 3:00 PM ET and he will also conduct one-on-one meetings during the event.

The company is commercializing products like sugarBEAT®, a continuous glucose monitor, and proBEAT™, a health tech product aimed at diabetes management. Nemaura is positioned in the growing diabetes market projected to reach $59 billion by 2025.

Nemaura Medical (Nasdaq: NMRD) provided a business update and financial results for Q2 FY2022, reporting total operating expenses of approximately $1.7 million. Key highlights include the launch of the beta version of Miboko, a metabolic health program, and a global commercial contract with MySugarWatch DuoPack for glucose monitors. Cash and cash equivalents decreased to roughly $26.8 million from $31.9 million. The company expects to recognize revenue from a recent order of 200,000 sensors, with delivery anticipated in Q4 2021.

Nemaura Medical (NASDAQ: NMRD) announces that CEO Faz Chowdhury will present at the Diabetes Technology Society Annual Meeting on November 4, 2021, at 2:00 PM ET. This virtual presentation will focus on innovative technologies aiding diabetes management. The meeting aims to foster connections between tech developers and users to create cost-effective tools for diabetes care, featuring regulatory updates from FDA officials. Nemaura Medical specializes in non-invasive wearable diagnostics and is currently commercializing sugarBEAT®, a continuous glucose monitor.

Nemaura Medical (NASDAQ: NMRD) has announced that CEO Faz Chowdhury, Ph.D., will present virtually at the 14th Annual LD Micro Main Event Conference on October 13 at 10:00 AM ET. The presentation aims to provide insights into Nemaura's advancements in non-invasive wearable diagnostic devices, including the sugarBEAT® and proBEAT™ products. Nemaura operates within the rapidly expanding global Type 2 diabetes and wearable health-tech markets, which are projected to reach substantial valuations in coming years.

Nemaura Medical (NASDAQ: NMRD) announces the beta launch of MiBoKo, a noninvasive glucose sensor combined with an AI mobile application aimed at improving metabolic health. This program, developed over 18 months, is expected to benefit a substantial market, including those with prediabetes and obesity, by measuring metabolic health scores related to glucose tolerance. Users will receive personalized feedback through an app, which tracks their metabolic data and offers actionable health insights. The beta program is currently available at no cost in North America, the U.K., and Europe.

Nemaura Medical (NASDAQ: NMRD) has signed a global commercial contract with MySugarWatch DuoPack Limited for its sugarBEAT® non-invasive continuous glucose monitor (CGM). This agreement allows the CGM to be offered in Duo-Packs with prescription medications for Type 2 diabetes, launching in Q4 2022. Nemaura placed an order for 200,000 CGMs to prepare for demand, anticipating supplying 800,000 sensors monthly. The contract enables Nemaura to continue direct sales of sugarBEAT® in various territories. The diabetes market is poised for substantial growth, reaching nearly $59 billion by 2025.

Nemaura Medical Inc. (NASDAQ: NMRD) has introduced its BEAT(R) diabetes platform, featuring the sugarBEAT(R) continuous glucose monitor (CGM) and proBEAT(TM) healthcare app. These innovations utilize AI to help patients manage diabetes effectively. With diabetes affecting 463 million individuals globally and causing approximately 3.4 million deaths annually, Nemaura aims to address this critical health issue. The company has submitted a PMA for sugarBEAT to the FDA and is actively commercializing its products in the U.S., targeting better diabetes management for patients.

Nemaura Medical Inc. (NASDAQ: NMRD) was featured in an editorial by NetworkNewsWire, highlighting the role of technology in addressing major healthcare challenges. The global healthcare market, valued at $8.45 trillion in 2018, is under pressure to improve efficiency and outcomes. Nemaura focuses on diabetes and obesity, offering noninvasive diagnostic devices like sugarBEAT, a CE-mark-approved glucose monitor, and proBEAT, an AI-driven subscription service. The company has submitted a PMA for sugarBEAT to the U.S. FDA, aiming to enhance diabetes management.